SOURCE: Universal DetectionTechnology

March 02, 2010 05:00 ET

Universal Detection Technology Responds to Harvard Poll on Anthrax

Harvard School of Public Health Survey Finds Many Americans Would Delay Taking Antibiotics After Anthrax Attack, UNDT CEO Says Treatment Can Begin After Positive Anthrax Identification

LOS ANGELES, CA--(Marketwire - March 2, 2010) - Universal Detection Technology ( (OTCBB: UNDT), a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, responded today to a survey that says nearly a third of Americans would delay in taking an antibiotic recommended by public health officials in the wake of an anthrax detect.

The poll, conducted by the Harvard School of Public Health (HSPH), found that if Americans were faced with a significant anthrax threat in their city or town, 89 percent would follow public health officials' recommendations for prophylactic antibiotics; however, over a third of those respondents (39 percent), would delay in taking those medications.

"Once a positive identification of a trace of anthrax is found, prophylactic antibiotics can be administered to first responders and others that might have come into contact with the deadly bioagent," said Jacques Tizabi, CEO of Universal Detection Technology. "UNDT's 5 agent biodetection kits can detect the presence of anthrax and four other agents commonly used as bioweapons in as little as three minutes, allowing for the immediate and appropriate health response to prevent deadly illness," continued Tizabi.

The complete survey from HSPH can be downloaded from the school's website:

For more information about Universal Detection Technology please visit or email

About Universal Detection Technology

Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the company, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products. For more information, please visit

Forward-Looking Statements

Except for historical information contained herein, the statements in this news release are forward-looking statements that involve known and unknown risks and uncertainties, which may cause the Company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact Information